Pharmacopeia Mulls Separation of Accelrys Software Unit from Discovery Activities | GenomeWeb

Largely due to an anticipated shortfall of $1 million in second-quarter earnings for its drug discovery business, Pharmacopeia is considering splitting its software business, Accelrys, from its discovery group.

While the company is not scheduled to announce its exact earnings until August 1, it estimated that its drug discovery revenues totaled about $6.8 million during the second quarter, while Accelrys brought in $19.5 million to $20 million. Revenue from Accelrys grew at an annual rate of about 35 percent, in line with the company’s expectations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.